Press Releases

Receive news via e-mail

Nov 12, 2009 Results From Chelsea Therapeutics' Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension to be Presented at 20th Annual International Symposium on the Autonomic Nervous System Nov 2, 2009 Chelsea Therapeutics Reports Third Quarter 2009 Results Nov 2, 2009 Chelsea Therapeutics Appoints Dr. William D. Schwieterman Chief Medical Officer Oct 28, 2009 Chelsea Therapeutics to Host Conference Call to Discuss Third Quarter 2009 Results Oct 27, 2009 Chelsea Therapeutics to Present at the Oppenheimer 20th Annual Healthcare Conference on Wednesday, November 4, 2009 Oct 20, 2009 Chelsea Therapeutics Presents Novel, Metabolically Inert Autoimmune Portfolio at the 2009 ACR Annual Scientific Meeting Oct 1, 2009 Chelsea Therapeutics to Host Conference Call to Discuss Droxidopa Phase III Results Today At 4:30 PM ET Oct 1, 2009 Additional Analysis Confirms Significant Symptomatic Benefit of Droxidopa in Treatment of Neurogenic Orthostatic Hypotension Sep 24, 2009 Chelsea Therapeutics Reports Preliminary Phase III Data of Droxidopa for Treatment of Symptomatic Neurogenic Orthostatic Hypotension Sep 15, 2009 Chelsea Therapeutics to Present At BioCentury's Newsmakers in the Biotech Industry Conference Sep 9, 2009 Chelsea Therapeutics Achieves Target Enrollment in Second Pivotal Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension Sep 2, 2009 Chelsea Therapeutics to Present At the Rodman and Renshaw 11th Annual Healthcare Conference On Wednesday, September 9, 2009 Aug 5, 2009 Chelsea Therapeutics Reports Second Quarter 2009 Results Jul 30, 2009 Chelsea Therapeutics to Host Conference Call to Discuss Second Quarter 2009 Results Jul 29, 2009 Chelsea Therapeutics Completes $13.3 Million in Registered Direct Offering Jul 28, 2009 Chelsea Therapeutics Appoints William Rueckert to Board of Directors Jul 23, 2009 Chelsea Therapeutics to Raise $12.6 Million in Registered Direct Offering Jun 30, 2009 Chelsea Therapeutics Achieves Target Enrollment in Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension Jun 29, 2009 Chelsea Therapeutics Added to Russell 3000 and Russell 2000 Indexes Jun 11, 2009 Chelsea Therapeutics to Present Data Demonstrating Efficacy of CH-4051 in Rat Collagen-Induced Arthritis Model at EULAR 2009 May 21, 2009 Chelsea Therapeutics to Present Phase II Intradialytic Hypotension Data in Late Breaking Clinical Trials Session At World Congress of Nephrology 2009 May 6, 2009 Chelsea Therapeutics Reports First Quarter 2009 Results Apr 29, 2009 Chelsea Therapeutics to Host Conference Call to Discuss First Quarter 2009 Results Apr 27, 2009 Chelsea Therapeutics Reports Positive Results From Phase I Trial of CH-4051 Mar 18, 2009 Chelsea Therapeutics Reports Positive Results From Phase II Trial of CH-1504 in Rheumatoid Arthritis Mar 13, 2009 Chelsea Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 Mar 4, 2009 Chelsea Therapeutics Reports Fourth Quarter and Full Year 2008 Results Mar 2, 2009 Chelsea Therapeutics Reports Positive Preliminary Results of Phase II Study of Droxidopa in Intradialytic Hypotension Feb 25, 2009 Chelsea Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2008 Results Feb 17, 2009 Chelsea Therapeutics Reports Findings From Open-Label Titration Phase of Pivotal Phase III Trials Feb 11, 2009 Chelsea Therapeutics to Present At the ROTH 21st Annual OC Growth Stock Conference On Monday, February 16, 2009 Jan 28, 2009 Chelsea Therapeutics Initiates Phase II Trial of Droxidopa in Fibromyalgia Nov 19, 2008 Chelsea Therapeutics Completes Enrollment in Phase II Trial of Droxidopa in Intradialytic Hypotension Nov 13, 2008 Chelsea Therapeutics Initiates Phase I Clinical Trial of CH-4051 Nov 12, 2008 Chelsea Therapeutics to Host Analyst and Institutional Investor Day in New York Nov 5, 2008 Chelsea Therapeutics Reports Third Quarter 2008 Results Nov 3, 2008 Chelsea Therapeutics Reports Significant Reduction in Severity of Symptoms During Titration Phase of Pivotal Droxidopa Study in Neurogenic Orthostatic Hypotension Oct 30, 2008 Chelsea Therapeutics to Present At the Rodman and Renshaw 10th Annual Healthcare Conference On Monday, November 10, 2008 Oct 29, 2008 Data From Chelsea Therapeutics' Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension to be Presented at 19th Annual International Symposium on the Autonomic Nervous System Oct 28, 2008 Chelsea Therapeutics Completes Enrollment in Phase II Trial of CH-1504 in Rheumatoid Arthritis Oct 27, 2008 Chelsea Therapeutics to Host Conference Call to Discuss Third Quarter 2008 Results Oct 21, 2008 Chelsea Therapeutics Announces Positive DSMB Recommendation for CH-1504 Phase II Trial in Rheumatoid Arthritis Oct 20, 2008 Chelsea Therapeutics to Present At the Oppenheimer 19th Annual Healthcare Conference On Tuesday, November 4, 2008 Sep 16, 2008 Chelsea Therapeutics to Present At the UBS Global Life Sciences Conference On Monday, September 22, 2008 Sep 2, 2008 Chelsea Therapeutics Begins Patient Dosing in Second Pivotal Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension Aug 26, 2008 Chelsea Therapeutics Receives Fast Track Designation for Droxidopa for Symptomatic Neurogenic Orthostatic Hypotension Aug 6, 2008 Chelsea Therapeutics Reports Second Quarter 2008 Results Jul 31, 2008 Chelsea Therapeutics to Host Conference Call to Discuss Second Quarter 2008 Results Jul 23, 2008 Chelsea Therapeutics Granted MHRA Approval to Begin Phase II Trial of Droxidopa in Fibromyalgia Jul 16, 2008 Chelsea Therapeutics Reports Progress in Phase II Trial of CH-1504 in Rheumatoid Arthritis Jun 30, 2008 William D. Schwieterman, M.D. Joins Chelsea Therapeutics' Board of Directors Jun 17, 2008 Chelsea Therapeutics Appoints Joseph Oliveto as Vice President Operations May 13, 2008 Chelsea Therapeutics Reports First Quarter 2008 Results May 7, 2008 Chelsea Therapeutics to Host Conference Call to Discuss First Quarter 2008 Results Apr 22, 2008 Chelsea Announces Publication of Clinical Autonomic Research Supplement Focusing On Neurogenic Orthostatic Hypotension Apr 8, 2008 Chelsea Therapeutics Gains Global Rights to I-3D Portfolio Targeting Autoimmune Disease and Transplant Rejection Mar 25, 2008 Chelsea Therapeutics Reports Significant Efficacy of CH-4051 in Reduction of Collagen-Induced Arthritis in Animal Model Mar 20, 2008 Chelsea Therapeutics to Present at the BioCentury Future Leaders in the Biotech Industry Conference Mar 11, 2008 Chelsea Therapeutics Reports Fourth Quarter and Full Year 2007 Results Mar 4, 2008 Chelsea Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2007 Financial Results Feb 19, 2008 Chelsea Therapeutics Receives Special Protocol Assessment for Pivotal Phase 3 Study of Droxidopa in Neurogenic Orthostatic Hypotension Feb 8, 2008 Two New Independent Directors Join Chelsea Therapeutics Feb 7, 2008 Chelsea Therapeutics Begins Patient Dosing in Pivotal Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension Feb 4, 2008 Chelsea Therapeutics to Present at 10th Annual BIO CEO & Investor Conference Jan 23, 2008 Chelsea Therapeutics Initiates Phase II Clinical Program in Rheumatoid Arthritis Jan 7, 2008 Chelsea Therapeutics Initiates Phase II Study of Droxidopa in Intradialytic Hypotension Nov 13, 2007 Chelsea Therapeutics Reports Third Quarter 2007 Results Nov 12, 2007 FDA Accepts Chelsea Therapeutics' Investigational New Drug Application for Droxidopa Nov 8, 2007 Chelsea Therapeutics Completes $48.9 Million in Registered Direct Offering Nov 7, 2007 Chelsea Therapeutics to Host Conference Call to Discuss Third Quarter 2007 Results On November 13, 2007 Nov 2, 2007 Chelsea Therapeutics to Raise $48.9 Million in Registered Direct Offering Sep 24, 2007 Chelsea Therapeutics Announces Phase III Protocols for Droxidopa Sep 12, 2007 Chelsea Therapeutics to Present At the ThinkEquity Partners 5th Annual Growth Conference Sep 10, 2007 Chelsea Therapeutics Resolves Bioavailability Issue and Reports Greater Than 10-Fold Improvement in Relative Bioavailability of New CH-1504 Formulation Aug 14, 2007 European Commission Grants Chelsea Therapeutics Two Orphan Medicinal Product Designations for Droxidopa Aug 7, 2007 Chelsea Therapeutics Reports Second Quarter 2007 Results Jul 31, 2007 Chelsea Therapeutics to Host Conference Call to Discuss Second Quarter 2007 Results on August 7, 2007 Jun 27, 2007 Chelsea Therapeutics Initiates CH-1504 Bioequivalence Study May 9, 2007 Chelsea Therapeutics Reports First Quarter 2007 Results May 2, 2007 Chelsea Therapeutics to Host Conference Call to Discuss First Quarter 2007 Results on May 9, 2007 Apr 11, 2007 Chelsea Therapeutics to Sponsor Orthostatic Hypotension Symposium and Host 2007 Analyst and Institutional Investor Day in New York Mar 22, 2007 Chelsea Therapeutics Completes $12.5 Million Equity Financing Mar 19, 2007 Chelsea Therapeutics Announces $12.5 Million Equity Financing Mar 12, 2007 Chelsea Therapeutics Reports Fourth Quarter and Full Year 2006 Results Mar 7, 2007 Chelsea Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2006 Financial Results Feb 7, 2007 Chelsea Therapeutics Elects Kevan Clemens, Ph.D., as Chairman of the Board Feb 1, 2007 Chelsea Therapeutics Reports Improved Pharmacokinetics of Its Disodium Salt of CH-1504 Jan 22, 2007 FDA Grants Chelsea Therapeutics Orphan Drug Designation for Droxidopa Jan 11, 2007 Chelsea Therapeutics Announces Results of European Phase IIb Trial of Droxidopa Nov 14, 2006 Chelsea Therapeutics Reports Third Quarter 2006 Results Nov 2, 2006 Chelsea Therapeutics to Present at the Rodman & Renshaw 8th Annual Global Healthcare Conference Oct 24, 2006 Chelsea Therapeutics to Present at C.E. Unterberg, Towbin Life Sciences Conference Oct 13, 2006 Chelsea Therapeutics to Present at BIO Investor Forum Sep 7, 2006 Chelsea Therapeutics Files Orphan Drug Application and Forms Scientific Advisory Board for Droxidopa Aug 30, 2006 Chelsea Therapeutics to Present at the Roth 2006 New York Conference Jul 18, 2006 Chelsea Therapeutics Appoints Veteran Pharmaceutical Executive to Management Team Jul 6, 2006 Chelsea Therapeutics to Present At CE Unterberg Towbin Emerging Growth Conference Jun 26, 2006 Chelsea Therapeutics to Present at the Jefferies Life Sciences Conference Jun 19, 2006 Phase I Results for Chelsea Therapeutics' Lead Compound CH-1504 to be Presented At EULAR 2006 Jun 6, 2006 Chelsea Therapeutics to Present at Pacific Growth Equities Life Sciences Growth Conference May 30, 2006 Chelsea Therapeutics Signs Exclusive Droxidopa License Agreement With Dainippon Sumitomo Pharma May 25, 2006 The Journal of Rheumatology Publishes Clinical Results from Pilot Study of Chelsea Therapeutics' Lead Product Candidate CH-1504 May 9, 2006 Chelsea Therapeutics Updates Product Pipeline Status and Clinical Development Priorities May 9, 2006 Chelsea Therapeutics and Active Biotech to Co-Develop Portfolio of Therapeutics Targeting Autoimmune Disease and Transplant Rejection May 8, 2006 Chelsea Therapeutics to Seek Orphan Drug Status and Begin Development of Droxidopa for Neurogenic Orthostatic Hypotension May 1, 2006 Chelsea Therapeutics Obtains NASDAQ Listing Approval Mar 8, 2006 Chelsea Therapeutics to Present at Sachs Associates North American Biotech Forum Feb 14, 2006 Chelsea Therapeutics Closes $21.5 Million Placement with Leading Biotech Investors Jan 23, 2006 Chelsea Therapeutics to Present at Friedland Undervalued Equities Conference Dec 21, 2005 Chelsea Therapeutics Reports Positive Preliminary Results From Phase Ib Trial of CH-1504 Nov 10, 2005 Lead Investigator to Present Positive Clinical Study Results for Chelsea Therapeutics' Lead Compound CH-1504 at ACR 2005 Annual Scientific Meeting Nov 1, 2005 Chelsea Therapeutics to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference Oct 20, 2005 Chelsea Therapeutics Completes Phase Ia Trial of CH-1504 Oct 18, 2005 Chelsea Therapeutics to Present at 3rd Annual PIPES Conference 2005 Oct 18, 2005 Chelsea Therapeutics to Present At C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference Oct 17, 2005 Chelsea Therapeutics to Present at BIO InvestorForum 2005 Oct 6, 2005 Chelsea Therapeutics to Present at BioPartnering Europe 2005 Conference Jul 28, 2005 Chelsea Therapeutics Announces New Ticker Symbol Jul 27, 2005 Chelsea Therapeutics Announces Change in Name and Reincorporation in Delaware Jun 9, 2005 Chelsea Therapeutics Initiates Phase I Clinical Trial of CH-1504 Jun 7, 2005 Chelsea Therapeutics Granted Approval from UK Health Authority to Begin Phase I Clinical Trials for CH-1504 Apr 29, 2005 Chelsea Therapeutics to Present at the Rodman & Renshaw Techvest Global Healthcare Conference Feb 16, 2005 Chelsea Therapeutics Completes Reverse Merger With Ivory Capital Jan 21, 2005 Chelsea Therapeutics and Ivory Capital Sign Definitive Merger Agreement Jan 11, 2005 Chelsea Therapeutics, Inc. Raises $14.5 million in Private Placement Sep 30, 2004 Chelsea Therapeutics, Inc. today announced the hiring of their core team of senior executives Jul 15, 2004 Chelsea Therapeutics, Inc. (formerly Aspen Therapeutics) announces new name and location May 1, 2004 Aspen Therapeutics announces the hiring of Simon Pedder, Ph.D. as President and Chief Executive Officer Mar 24, 2004 Aspen Therapeutics announces licensing agreement with Dr. Gopal Nair, PhD of the University Of South Alabama College Of Medicine.